Drug Patents owned by Akcea Theraps

1. List of Tegsedi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7015315 AKCEA THERAPS Gapped oligonucleotides
Mar, 2023

(a month from now)

US7101993 AKCEA THERAPS Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(6 months from now)

US8101743 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2025

(2 years from now)

US9061044 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399774 AKCEA THERAPS Modulation of transthyretin expression
Apr, 2031

(8 years from now)

US8697860 AKCEA THERAPS Diagnosis and treatment of disease
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 5, 2023
Orphan Drug Exclusivity (ODE) Oct 5, 2025

Drugs and Companies using INOTERSEN SODIUM ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 05 October, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in